Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Debt: 2020-2022

Historic Total Debt for Mereo BioPharma Group (MREO) over the last 3 years, with Dec 2022 value amounting to $486,000.

  • Mereo BioPharma Group's Total Debt fell 97.49% to $486,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $486,000, marking a year-over-year decrease of 97.49%. This contributed to the annual value of $486,000 for FY2022, which is 97.49% down from last year.
  • Latest data reveals that Mereo BioPharma Group reported Total Debt of $486,000 as of FY2022, which was down 97.49% from $19.4 million recorded in FY2021.
  • Mereo BioPharma Group's Total Debt's 5-year high stood at $21.3 million during FY2020, with a 5-year trough of $486,000 in FY2022.
  • Moreover, its 3-year median value for Total Debt was $19.4 million (2021), whereas its average is $13.7 million.
  • Data for Mereo BioPharma Group's Total Debt shows a maximum YoY crashed of 97.49% (in 2022) over the last 5 years.
  • Over the past 3 years, Mereo BioPharma Group's Total Debt (Yearly) stood at $21.3 million in 2020, then decreased by 8.82% to $19.4 million in 2021, then crashed by 97.49% to $486,000 in 2022.